Yahoo Finance

DuPont de Nemours is a leading specialty chemicals company, formerly known as DowDuPont. It has two business segments: Electronics & Industrial and Water & Protection. The Electronics & Industrial segment supplies materials and printing systems to the printing industry and materials for the fabrication of semiconductors and integrated circuits. The Water & Protection segment provides engineered products and integrated systems for worker safety, water purification and separation, transportation, energy, medical packaging, and building materials.

Stocks were modestly lower on Wednesday morning after revised GDP data. The second estimate of U.S. GDP was revised down to 3.2% from the advance estimate of 3.3%. The update reflects upward revisions in state and local government spending and consumer spending, which were more than offset by a reduction in private inventory investment. The S&P 500 was down less than 0.1%, the Dow fell 0.2% and the Nasdaq lost 0.3%. Crude oil traded just above $78 per barrel and gold was down $2 to $2042 per ounce.

Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022. That's a recent rarity, as for the past decade-plus, the performance record has favored growth. But the tide turned in 2022. The rollout of COVID-19 vaccines gave a lift to some of the cyclical companies (energy and regional banks) that had lagged in recent quarters, and value stocks outpaced growth stocks that year. While growth stocks have retaken the lead since 2023, the Federal Reserve continues to keep interest rates high to fend off inflation. This could possibly cap multiple expansion for growth companies in coming quarters. In any event, the value sector is the place to achieve income.

Tuesday was a solid day for biotechnology stocks -- and not the large-cap names that dominate some ETFs, but rather smaller issues, some of which are unknown to many. First off, we have talked about how important ETF selection is -- as even names in the same industry can be vastly different. The two main biotech ETFs, the iShares Biotech (IBB) and the SPDR S&P Biotech (XBI), are about the same size, with over $7 billion in net assets. But that is where the similarities end.